Clinical trials: Malignant Neoplasm of the Breast
Breast Cancer, Breast Lesions of Uncertain Malignant Potential (B3 Lesions)
BRCA1, RASSF1A and PTEN Methylation in Breast Lesions of Uncertain Malignant Potential
This prospective interventional diagnostic study evaluates the clinical utility of methylation analysis of BRCA1, RASSF1A and PTEN genes in breast lesions of uncertain malignant potential (B3 lesions).
- Trial name
- NCT07416500
- Testing
- MS-MLPA Methylation Analysis
- Where
- Slovenia
- Volunteers
- 301 people
- Sponsor
- Institute of Oncology Ljubljana
HR+/HER2- Breast Cancer, Metastatic Disease
Abemaciclib for the Treatment of Luminal Metastatic breAst caNcer in the Real-life Clinical pracTice in Russia.
The ATLANT study is prospective, multicentre, non-interventional, observational study. Patients with HR+/HER2-negative metastatic breast cancer received abemaciclib as monotherapy or in combination with endocrine therapy.
- Conditions
- HR+/HER2- Breast Cancer, Metastatic Disease, Аdvanced Disease
- Trial name
- ATLANT (NCT05789771)
- Testing
- Abemaciclib
- Where
- Russia
- Volunteers
- 136 people
- Sponsor
- Blokhin's Russian Cancer Research Center
Breast Neoplasm Female, Arthralgia
Pilot Observational Study Examining the Effect of Endocrine Therapy on Aging
The goal of this pilot observational study is to learn about the feasibility of collecting patient-reported data and stool and blood samples from patients age 65 and older treated with aromatase inhibitor therapy for breast…
- Conditions
- Breast Neoplasm Female, Arthralgia, Aging
- Trial name
- BETA (NCT05700006)
- Testing
- Aromatase inhibitor
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- University of Michigan
Malignant Breast Tissue Neoplasm
Is Dietary Nitrate Effective in Reducing Aerobic Glycolysis in Breast Cancer?
Breast cancer is the most prevalent cancer affecting women, with 1 in 8 women in the UK developing breast cancer in their life time.
- Trial name
- BEET (NCT03944226)
- Testing
- Beetroot juice
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- University of Aberdeen
Breast Cancer, Head and Neck Cancer
Using Traditional Acupuncture in the Management of Cancer Treatment Related Lymphoedema
RATIONALE: Acupuncture and moxibustion may improve well-being and quality of life in patients with lymphedema caused by breast cancer or head, neck, and throat cancer.
- Conditions
- Breast Cancer, Head and Neck Cancer, Lymphedema
- Trial name
- AMWELL-SL (NCT00828516)
- Testing
- Acupuncture and moxibustion
- Where
- United Kingdom
- Volunteers
- 56 people
- Sponsor
- East and North Hertfordshire NHS Trust
Breast Neoplasm
Decitabine Plus Carboplatin in the Treatment of Metastatic TNBC
To evaluate the effect of novel DNA demethylating agents in the treatment of metastatic TNBC
- Trial name
- DETECT (NCT03295552)
- Testing
- Decitabine, Carboplatin
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Refractory Head and Neck Cancer, Squamous Cell Carcinoma, Skin
Study of HF10 in Patients With Refractory Head and Neck Cancer or Solid Tumors With Cutaneous and/or Superficial Lesions
The purpose of this study is to determine whether HF10 is safe and effective in the treatment of head and neck cancer or solid tumors with cutaneous and/or superficial lesions.
- Conditions
- Refractory Head and Neck Cancer, Squamous Cell Carcinoma, Skin, Carcinoma of the Breast, Malignant Melanoma
- Trial name
- NCT01017185
- Testing
- HF10
- Where
- 5 sites in United States
- Volunteers
- 28 people
- Sponsor
- Takara Bio Inc.
Breast Cancer, Hypercalcemia of Malignancy
Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Zoledronate may prevent bone loss and stop the growth of tumor cells in bone.
- Conditions
- Breast Cancer, Hypercalcemia of Malignancy, Metastatic Cancer, Pain
- Trial name
- NCT00060138
- Testing
- monoclonal antibody CAL, zoledronic acid
- Where
- United States
- Sponsor
- Chugai Pharmaceutical
Breast Cancer, Endometrial Cancer
BI 2536 in Treating Patients With Recurrent or Metastatic Solid Tumors
RATIONALE: BI 2536 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects and how well BI 2536 works in treating patients with…
- Conditions
- Breast Cancer, Endometrial Cancer, Head and Neck Cancer, Melanoma (Skin)
- Trial name
- NCT00526149
- Testing
- BI 2536, high performance liquid chromatography, mass spectrometry
- Where
- Belgium
- Volunteers
- 76 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
Breast Cancer, Malignant Melanoma
Transfected Dendritic Cell Based Therapy for Patients With Breast Cancer or Malignant Melanoma
The primary aim of this study is to evaluate the toxicity of the vaccine and the combination of the vaccine and Cyclophosphamide, and to evaluate the immune response induced by the vaccine.
- Trial name
- NCT00978913
- Testing
- DC vaccine
- Where
- Denmark
- Volunteers
- 31 people
- Sponsor
- Inge Marie Svane
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer
This phase I trial investigates the side effects and best dose of abexinostat and palbociclib when given together with fulvestrant in treating patients with breast or gynecologic cancer.
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- NCT04498520
- Testing
- Abexinostat Tosylate, Fulvestrant, Palbociclib
- Sponsor
- Pamela Munster
Breast Cancer, Circulating Tumor Cell
CTCs in Breast Cancer After Neoadjuvant Treatment and Surgery: a Multicenter, Prospective Clinical Trial
The GILUPI CellCollector® is the first in vivo CTC isolation product worldwide, which is CE approved. This is a prospective, multicenter study to evaluate the prognostic value of circulating tumor cells in breast cancer patients…
- Trial name
- CTCNeoBC-E (NCT05360290)
- Testing
- GILUPI CellCollector®
- Where
- China
- Volunteers
- 484 people
- Sponsor
- RenJi Hospital
Advanced Solid Tumors, Metastatic Pancreatic Cancer
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Background: Metastasis is the spread of cancer from one organ to a nonadjacent organ. It causes 90% of cancer deaths. No treatment specifically prevents or reduces metastasis. Researchers hope a new drug can help.
- Conditions
- Advanced Solid Tumors, Metastatic Pancreatic Cancer, Pediatric Solid Tumor, Advanced Breast Cancer
- Trial name
- NCT04222413
- Testing
- Metarrestin
- Where
- 2 sites in United States
- Volunteers
- 116 people
- Sponsor
- National Cancer Institute (NCI)
Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma
Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer
This phase I/II trial investigates the side effects of genetically engineered cells called FH-MagIC TCR-T cells and how well they work with atezolizumab in treating patients with triple negative breast cancer, urothelial cancer…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Triple-Negative Breast Carcinoma
- Trial name
- NCT04639245
- Testing
- Atezolizumab, Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Fred Hutchinson Cancer Center
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases
This early phase I trial tests the use of a radioactive tracer (a drug that is visible during an imaging test) known as 18F-FMAU, for imaging with positron emission tomography/computed tomography (PET/CT) in patients with brain…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Glioma, Malignant Brain Neoplasm
- Trial name
- NCT04752267
- Testing
- Computed Tomography, 18F-FMAU, Multiparametric Magnetic Resonance Imaging
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of Southern California
Cancer
Laboratory Assay in Determining Cancer Resistance in Patients With Metastatic Cancer and in Healthy Participants
RATIONALE: Studying samples of blood and tissue in the laboratory from patients with cancer and from healthy participants may help doctors learn more about cancer.
- Trial name
- NCT00899496
- Testing
- immunological diagnostic method, physiologic testing
- Where
- United States
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Triple Negative Breast Neoplasms
A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer
This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer
- Trial name
- BEGONIA (NCT03742102)
- Testing
- Durvalumab, Capivasertib, Oleclumab
- Where
- 32 sites in United States, Canada and 4 more
- Volunteers
- 243 people
- Sponsor
- AstraZeneca
Metastatic Malignant Neoplasm in the Bone, Stage IV Breast Cancer AJCC v6 and v7
Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer
This phase I trial studies the side effects and best dose of ruxolitinib phosphate when given together with pembrolizumab in treating patients with stage IV triple negative breast cancer that has spread to other places in the…
- Conditions
- Metastatic Malignant Neoplasm in the Bone, Stage IV Breast Cancer AJCC v6 and v7, Triple-Negative Breast Carcinoma
- Trial name
- NCT03012230
- Testing
- Laboratory Biomarker Analysis, Pembrolizumab, Ruxolitinib Phosphate
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Mayo Clinic
Solid Tumor, Adult, Triple Negative Breast Cancer
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
This clinical study is an open-label, Phase 1, dose-escalation study to determine the safety, tolerability, and efficacy of the drug product produced by Administering CRX100 alone and in combination with Pembrolizumab in advanced…
- Conditions
- Solid Tumor, Adult, Triple Negative Breast Cancer, Colorectal Cancer, Hepatocellular Carcinoma
- Trial name
- NCT04282044
- Testing
- CRX100 suspension for infusion, Fludarabine, Cyclophosphamide
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- BioEclipse Therapeutics
Breast Cancer, Lung Cancer
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
RATIONALE: Gathering information about how often osteonecrosis of the jaw occurs in patients receiving zoledronic acid for bone metastases may help doctors learn more about the disease and provide the best follow-up care.
- Conditions
- Breast Cancer, Lung Cancer, Metastatic Cancer, Multiple Myeloma
- Trial name
- NCT00874211
- Testing
- assessment of therapy complications
- Where
- 453 sites in United States, Mexico and 1 more
- Volunteers
- 3,571 people
- Sponsor
- SWOG Cancer Research Network